Study on the role of bifidobacteria in FOLFOX6 chemotherapy for gastric cancer

ObjectiveTo study the role of bifidobacteria in FOLFOX6 chemotherapy for gastric cancer.

MethodsEighty patients with gastric cancer were randomly divided into the observation group and control group according to random number table method.The control group were treated with FOLFOX6 chemotherapy, and the observation group were additionally treated with bifidobacteria on the basis of the control group.The total number of lymphocytes(TLC), white blood cell count(WBC), neutrophils (N), intestinal flora, gastrointestinal symptom rating scale(GSRS), clinical efficacy and adverse reaction were compared between two groups.

ResultsAfter chemotherapy, the levels of TLC, WBC and N in two groups increased in different degrees compared before chemotherapy(P < 0.05), the levels of TLC and N in control group were lower than those in observation group(P < 0.01), and there was no statistical significance in the level of WBC between two groups(P>0.05).After chemotherapy, the level of lactobacillus in control group was lower than that in observation group(P < 0.01), and the levels of enterobacter, enterococcus and GSRS were higher than those in observation group(P < 0.05 to P < 0.01).There was no statistical significance in total remission rate between two groups(P>0.05).The incidence rate of adverse reactions in observation group was lower than that in control group(P < 0.05).

ConclusionsBifidobacterium can improve the body's immunity and gastrointestinal flora distribution and symptoms, and thereby which reduces the adverse reaction of FOLFOX6 chemotherapy.